Rani Therapeutics (RANI) Projected to Post Earnings on Wednesday

Rani Therapeutics (NASDAQ:RANI) will likely be releasing its earnings data before the market opens on Wednesday, March 19th. Analysts expect Rani Therapeutics to post earnings of ($0.24) per share for the quarter.

Rani Therapeutics Stock Down 1.4 %

Shares of NASDAQ:RANI opened at $1.46 on Wednesday. The stock has a fifty day simple moving average of $1.49 and a two-hundred day simple moving average of $1.96. The stock has a market capitalization of $83.64 million, a price-to-earnings ratio of -1.38 and a beta of 0.14. Rani Therapeutics has a 12-month low of $1.24 and a 12-month high of $8.75. The company has a current ratio of 1.60, a quick ratio of 1.60 and a debt-to-equity ratio of 2.34.

Insider Activity at Rani Therapeutics

In related news, insider Kate Mckinley bought 17,960 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The shares were bought at an average price of $1.67 per share, for a total transaction of $29,993.20. Following the completion of the acquisition, the insider now owns 17,960 shares of the company’s stock, valued at $29,993.20. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 53.30% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on RANI. Canaccord Genuity Group reiterated a “buy” rating and set a $9.00 price objective on shares of Rani Therapeutics in a research note on Wednesday, February 26th. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Rani Therapeutics in a research report on Friday, February 7th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Rani Therapeutics currently has a consensus rating of “Buy” and an average price target of $12.33.

Rani Therapeutics Company Profile

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.